TG Therapeutics, Inc. Opens Expansion Cohorts in Its Phase I/II Trial of TG …PharmaLive (press release) (subscription)Coupled with the clinical activity seen in both rituximab relapsed and refractory patients across the dose levels tested thus far, w…
 Healio |
Inotuzumab/rituximab combination shows promise in NHL
Healio The phase 1/2 study aimed to determine the maximum tolerated dose of inotuzumab ozogamicin plus rituximab (Rituxan, Genentech/Idec Pharmaceuticals) in a cohort of patients with relapsed/refractory CD20+/CD22+ B-cell non-Hodgkin’s lymphoma. |
TG Therapeutics, Inc. Opens Expansion Cohorts in Its Phase I/II Trial of TG …GlobeNewswire (press release)NEW YORK, Feb. 11, 2013 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (TGTX) today announced that it has amended its Phase I/II study of single agen…
B-cell depletion in SLE: clinical and trial experience with rituximab and …7thSpace Interactive (press release)In recent years there have been many publications regarding the experience in SLE of B-cell depletion utilising rituximab, an anti-CD20 mAb…
|
Clinical Notes: Users Deem E-Cigs Safer
MedPage Today In comments made to industry analysts at a meeting, the company’s CEO Robert Bradway said Amgen would be launching biosimilar versions of bevacizumab (Avastin), adalimumab (Humira), infliximab (Remicade), trastuzumab (Herceptin), rituximab … |
|
8 Biotech Growth Names: Greg Wade
Seeking Alpha Is this drug going to be tested in all of the old indications that rituximab (Rituxan; Genentech USA Inc./Biogen Idec Inc.) was developed for originally? GW: It has shown some activity in a number of them. I don’t actually have a breakdown of where … |
|
Eight Biotech Growth Names: Greg Wade
Jutia Group Is this drug going to be tested in all of the old indications that rituximab (Rituxan; Genentech USA Inc./Biogen Idec Inc. (BIBB:NASDAQ)) was developed for originally? GW: It has shown some activity in a number of them. I don’t actually have a … |
HealioLenalidomide, rituximab combination shows promise in CLLHealioThe study regimen included rituximab 375 mg/m2 IV administered weekly during cycle one and on day 1 of cycles three to 12. Oral lenalidomide was initiated on day 9 of cycle one at 10 m…
|
‘New Technologies to Capture Over 10% of the Antibody Therapeutics Market by …
EIN News (press release) You can see Roche getting in on the ground floor there with what they’re doing with obinituzumab and T-DM1, using engineering and ADC technologies to extend their rituximab and trastuzumab franchises. T-DM1 is potentially a major watershed for the … |
Meds from foreign plants complicate counterfeit searchFiercePharma ManufacturingOne of the drugs the center bought was rituximab, the foreign version of the cancer drug sold as Rituxan in the U.S. Investigators found that it was manufactured at a Roche…